SEC Tracker
Get the app

MetaVia MTVA

MetaVia appoints Sarah Browne as CMO

Form
8-K
Filed
Importance
Major
  1. Appointed on October 12, 2026
  2. Dr. Browne has 20+ years in clinical development
  3. Focus on liver and metabolic diseases
  4. Advanced pemvidutide through Phase 2

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when MetaVia files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Oragenics OGEN public float $3M, Jun 30, 2025
  2. Inhibitor Therapeutics INTI public float $3M, Jun 30, 2025
  3. PTC Therapeutics PTCT public float $3M, Jun 30, 2025
  4. Propanc Biopharma PPCB public float $3M, Dec 31, 2025
  5. Integrated Biopharma INBP public float $3M, Dec 31, 2025